Stocks · News reference
The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Read original at benzingaHC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
Read original at benzingaPiper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
Read original at benzinga